RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR 300 MG
TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG · DIN 02518716 · LABORATOIRE RIVA INC.
Health Canada status: CANCELLED POST MARKET
What is RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR?
RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR 300 MG contains TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02518716, held by LABORATOIRE RIVA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02518716 |
|---|---|
| Brand name | RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR |
| Generic / active ingredient | TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Jul-2025 |
What can be used instead?
Other Canadian products sharing ATC code J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ. 5 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | APOTEX INC | MARKETED | DIN 02468247 |
| AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02478404 |
| JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02519461 |
| MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02461412 |
| TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02393549 |
| ATRIPLA | 200 MG | TABLET | GILEAD SCIENCES, LLC | CANCELLED POST MARKET | DIN 02300699 |
| PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 600 MG | TABLET | PHARMASCIENCE INC | DORMANT | DIN 02487284 |
| SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02484676 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.